300006 Chongqing Lummy Pharmaceutical
- 2.92
- +0.01+0.34%
Chongqing Lummy Pharmaceutical News
Laimei Pharmaceutical (300006.SZ): No synthetic biology-related research has been carried out
Gelonghui, May 14 | Laimei Pharmaceutical (300006.SZ) said on the investor interactive platform that up to now, the company has not carried out research related to synthetic biology.
Laimei Pharmaceutical (300006.SZ): The participating company Guangxi Agleya is currently not conducting research on protein drugs for Alzheimer's disease
Gelonghui, May 14 | Laimei Pharmaceutical (300006.SZ) said on the investor interactive platform that the company's shareholding company, Guangxi Aglaia, has not currently conducted research on protein drugs for Alzheimer's disease.
Laimei Pharmaceutical (300006.SZ): Net loss of 4.575,300 yuan in the first quarter
On April 23, Ge Longhui Pharmaceutical (300006.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 181 million yuan, a year-on-year decrease of 20.09%; net profit attributable to shareholders of listed companies - 4,5753 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 7.4337 million yuan; basic earnings per share - 0.0043 yuan.
Lemei Pharmaceutical (300006.SZ): Currently, tadalafil tablets sold as agents by the company account for a small share of revenue
Gelonghui, April 18 | Lemei Pharmaceutical (300006.SZ) said on the investor interactive platform that currently the company sells tadalafil tablets as agents account for a small share of revenue. Currently, the company is mainly focusing on core advantage products, actively expanding the market of its flagship product Canalin in clinical fields such as thyroid, broadening the generic drug market, actively introducing new products and technologies, etc., and increasing the company's revenue level.
Lamy Pharmaceuticals (300006.SZ): Kangdesai's CUD005 injection received a notice of approval for drug clinical trials
Gelonghui, March 28, 丨 Lemei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd. participated in a self-developed macrophage CUD005 injection (“CUD005 injection”) of Sichuan Kangdesai Medical Technology Co., Ltd. (“CUD005 injection”), a self-developed macrophage cell CUD005 injection (“CUD005 injection” for short) to treat decompensated liver cirrhosis, obtained implied approval for drug clinical trials and obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. Cirrhosis of the liver is a common chronic progressive tissue damage liver disease. The causes include long-term alcohol abuse, obesity, metabolic disorders,
Laimei Pharmaceutical (300006.SZ) subsidiary's endoscopic products obtained medical device registration certificate
Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Hainan Laimei Medical Devices Co., Ltd. (hereinafter referred to as “Laimei Medical Devices”), a holding subsidiary of the company, received two “medical device registration certificates” issued by the Hainan Drug Administration. The products are: “electromechanical endoscopic image processor” and “disposable electronic bronchial imaging catheter”. The single-use electronic bronchial imaging catheter and electronic endoscopic image processor, which obtained the “Medical Device Registration Certificate” this time, is an endoscopic product developed by Laimei Medical Devices. This product can directly observe patient images, which is beneficial
Laimei Pharmaceutical (300006.SZ): net loss of 8.9273 million yuan in 2023
Gelonghui, March 22丨Laimei Pharmaceutical (300006.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 896 million yuan, an increase of 1.24% over the previous year; net profit attributable to shareholders of listed companies was -8.9273 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -59.333 million yuan; and basic earnings per share was -0.0085 yuan.
Laimei Pharmaceutical (300006.SZ): The ban on 244 million restricted shares will be lifted on March 22
On March 19, Ge Longhui Pharmaceutical (300006.SZ) announced an indicative announcement on the listing and circulation of restricted shares issued to specific targets. The shares that have been lifted are the company's shares issued to specific targets in 2021. The total number of shareholders applying to lift sales restrictions is 3. The number of shares that have been lifted this time is 244 million shares, accounting for 23.08% of the company's total share capital. The listing and circulation date for the shares whose sales restrictions have been lifted is March 22, 2024 (Friday).
Lemei Pharmaceutical (300006.SZ): Obtained the drug registration certificate for omeprazole magnesium enteric tablets (20mg)
Gelonghui, March 19 | Lemei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for 20 mg omeprazole magnesium enteric tablets approved and issued by the State Drug Administration. Omeprazole magnesium enteric tablets are mainly used to treat duodenal ulcers, stomach ulcers and reflux esophagitis; use in combination with antibiotics to treat duodenal ulcers caused by Helicobacter pylori; treat peptic ulcers or gastroduodenal erosions associated with nonsteroidal anti-inflammatory drugs; prevent peptic ulcers, gastroduodenal erosion or indigestion caused by nonsteroidal anti-inflammatory drugs;
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug
China's National Medical Products Administration approved the application of Guangxi Wuzhou Zhongheng Group's (SHA:600252) unit, Chongqing Lummy Pharmaceutical (SHE:300006), to increase the dosage of
Zhongheng Group (600252.SH): Lemei Pharmaceutical's “injectable esomeprazole sodium” was approved to increase the specification by 20 mg
Zhongheng Group (600252.SH) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd., a holding subsidiary of the company (...
Laimei Pharmaceutical (300006.SZ): As of February 29, 2024, the number of shareholders of the company was 34,301
Gelonghui March 13 | Laimei Pharmaceutical (300006.SZ) said on many investor platforms that as of February 29, 2024, the number of shareholders of the company was 34,301.
Laimei Pharmaceutical (300006.SZ): The core product Canalin has been selling well in recent years
Gelonghui, March 5 | Lemei Pharmaceutical (300006.SZ) said on the investor interactive platform that the company's core product, Canalin, has been selling well in recent years. The product has received clinical expert consensus in various fields such as thyroid, mammary, gastrointestinal, and gynecological tumors. It is highly recognized by academic institutions and the market, and has now become a first-line routine medication for thyroid surgery in China. Currently, the company is continuously expanding and enhancing Canalin's market potential in various fields such as gastrointestinal and breast.
Lummy Pharma Gets Nod to Market Nicorandil
Chongqing Lummy Pharmaceutical (SHE:300006) received approval from China's National Medical Products Administration to market raw drug ingredient Nicorandil, according to a Friday disclosure. The raw
Laimei Pharmaceutical (300006.SZ): Remy Longyu obtained approval notice for marketing application for Nicordil raw materials (specification: 4.00kg/bag, 1 bag/bottle)
Gelonghui, March 1 | Laimei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (“Laimei Longyu”), a wholly-owned subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., received the approval and issuance of Nicodyl (Specification: 4.00kg/bag, 1 bag/bottle) “Notice of Approval of Application for Chemical Ingredients” by the State Drug Administration. Nicordil for injection is mainly used for unstable angina pectoris and acute heart failure, improves coronary microcirculation, can effectively reduce cardiovascular events, and can significantly reduce the risk of acute coronary syndrome. Clinical patients benefit a lot.
Laimei Pharmaceutical (300006.SZ): As of February 20, 2024, the number of shareholders of the company was 34,151
Gelonghui Feb. 26 | Laimei Pharmaceutical (300006.SZ) said on the investor interactive platform that as of February 20, 2024, the number of shareholders of the company was 34,151.
Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) Popularity With Investors Under Threat As Stock Sinks 28%
Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) shareholders that were waiting for something to happen have been dealt a blow with a 28% share price drop in the last month. The drop over the
Laimei Pharmaceutical (300006.SZ): Pre-loss of 800,000 yuan to 12.00 million yuan in 2023
Gelonghui, January 30, 丨 Laimei Pharmaceutical (300006.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was RMB 800,000 to RMB 12,000,000, with a loss of RMB 687.091 million for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of RMB 73.0 million to 77.0 million yuan, and a loss of 115.3328 million yuan for the same period last year. During the reporting period, Sichuan Kangdesai Medical Technology Co., Ltd. (hereinafter referred to as “Kangdesai”), the company's former holding subsidiary, implemented equity incentives in the form of capital increases. The company and
Laimei Pharmaceutical (300006.SZ): As of January 10, 2024, the number of shareholders of the company was 34,307
Gelonghui January 15 | Laimei Pharmaceutical (300006.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 34,307.
Further Weakness as Chongqing Lummy Pharmaceutical (SZSE:300006) Drops 8.7% This Week, Taking Three-year Losses to 55%
Investing in stocks inevitably means buying into some companies that perform poorly. But long term Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) shareholders have had a particularly rough ri
Analysis
Price Target
No Data
